Symptomatic AtherosSymptomatic Non-acute Internal Carotid Artery Occlusion, SNICAO
Conditions
Interventions
Observation Group:None
Sponsors
Yulin First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age> 18 years old; 2. Unilateral internal carotid artery occlusion detected by MRA/CTA/DSA; 3. The time from vascular occlusion to treatment is more than 24 hours (confirmed by imaging or inferred from the event of responsibility.; 4. Ipsilateral internal carotid artery occlusion related to liability events within the past 12 months, including ischemic stroke, TIA, or one or more of the transient monocular amaurosis (patients with only dizziness or headache are considered asymptomatic.; 5.mRS<=3; 6. Patients and their families are willing to participate in this trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Occlusion caused by the following non-atherosclerotic diseases: such as arterial dissection, Takayasu's arteritis, moyamoya disease; vascular disease caused by herpes simplex virus, herpes zoster virus or other viruses; neurosyphilis; leptospira vasculitis; Any type of intracranial infection; radiation-induced vascular occlusion; fibromuscular dysplasia; sickle red cell anemia, etc.; 2. Previous history of primary intracranial or ventricular hemorrhage; 3. Active bleeding or known bleeding tendency within 30 days; 4. Cerebrovascular history of extracranial-intracranial vascular bypass grafting and/or occlusive vascular recanalization. 5. Patients with severe heart, liver, kidney, lung and other important organ diseases or functional failure; Those with tumors. 6. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| New stroke or death within 30 days after treatment;The incidence of composite endpoint events of ipsilateral ischemic stroke from 30 days to 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptomatic hemorrhage within 30 days after treatment;The incidence of all strokes at 3 months, 6 months, 12 months and 24 months after treatment;The incidence of all deaths at 3 months, 6 months, 12 months and 24 months after treatment;The incidence of all strokes and deaths at 3 months, 6 months, 12 months and 24 months after treatment;The mRS scores at 3 months, 6 months, 12 months and 24 months after treatment; | — |
Countries
China
Contacts
Public ContactLin Yanni
Yulin First People's Hospital
Outcome results
None listed